AAPL 258.2 1.1478% MSFT 439.33 0.9374% NVDA 140.22 0.3938% GOOGL 196.11 0.7604% GOOG 197.57 0.8062% AMZN 229.05 1.7729% META 607.75 1.317% AVGO 239.68 3.1547% TSLA 462.28 7.3572% TSM 206.33 -0.4967% LLY 795.67 -0.0766% V 320.65 1.0813% JPM 242.31 1.6444% UNH 506.1 -0.0474% NVO 87.37 -1.5105% WMT 92.68 2.5789% LVMUY 132.15 0.1516% XOM 106.4 0.0941% LVMHF 655.0 -0.2543% MA 535.71 1.2761%
Last update at 2024-12-24T14:30:00Z
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
Tue 08 Oct 24, 05:05 PMAstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
Mon 07 Oct 24, 12:04 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 7582.26M | 6847.10M | 6391.02M | 4626.16M | 3953.56M |
| Minority interest | -140.66000M | -82.93900M | 768.78M | 1056.44M | 477.34M |
| Net income | 6091.39M | 5605.19M | 5159.65M | 3714.11M | 3210.01M |
| Selling general administrative | 1172.84M | 1009.82M | 945.71M | 748.51M | 7121.07M |
| Selling and marketing expenses | 10337.42M | 10443.42M | 9377.62M | 8712.08M | - |
| Gross profit | 22256.41M | 21135.09M | 18685.32M | 15910.98M | 12218.99M |
| Reconciled depreciation | 1047.94M | 865.47M | 808.81M | 691.60M | 655.25M |
| Ebit | 7559.09M | 6817.40M | 6070.20M | 4658.59M | 3613.72M |
| Ebitda | 8607.03M | 7682.87M | 6879.01M | 5350.18M | 3976.72M |
| Depreciation and amortization | 1047.94M | 865.47M | 808.81M | 691.60M | - |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 7559.09M | 6817.40M | 6070.20M | 4600.18M | 3976.72M |
| Other operating expenses | 24177.27M | 21071.92M | 18885.54M | 17503.01M | 14483.45M |
| Interest expense | 24.89M | 7.66M | 12.23M | 32.43M | 76.90M |
| Tax provision | 1350.21M | 1158.97M | 1162.01M | 892.81M | 766.71M |
| Interest income | - | - | - | - | - |
| Net interest income | -24.89100M | -7.66400M | -12.23200M | -32.42600M | -76.90096M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 1350.21M | 1158.97M | 1162.01M | 892.81M | 766.71M |
| Total revenue | 30936.90M | 27866.87M | 24942.20M | 22103.19M | 18468.73M |
| Total operating expenses | 15496.78M | 14340.14M | 12628.65M | 11310.80M | 8233.71M |
| Cost of revenue | 8680.49M | 6731.78M | 6256.88M | 6192.21M | 6249.74M |
| Total other income expense net | 23.17M | 29.70M | 320.82M | 25.98M | -23.15082M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 6232.05M | 5688.12M | 5229.01M | 3733.35M | 3186.85M |
| Net income applicable to common shares | - | 5605.19M | 5159.65M | 3714.11M | 3080.80M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 41769.77M | 34741.58M | 30070.21M | 26318.32M | 22694.43M |
| Intangible assets | 1908.11M | 467.85M | 508.74M | 1135.66M | 805.39M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 177.75M | 36.57M | 562.22M | 1434.78M |
| Total liab | 10127.90M | 7913.35M | 6969.13M | 6800.16M | 7672.00M |
| Total stockholder equity | 30197.53M | 25986.67M | 22332.29M | 18461.72M | 15022.43M |
| Deferred long term liab | 35.81M | 41.98M | 14.15M | 8.08M | 7.02M |
| Other current liab | 6652.38M | 5565.00M | 4836.44M | 4712.52M | 3965.32M |
| Common stock | 10899.41M | 10899.41M | 10899.41M | 10899.41M | 10899.41M |
| Capital stock | 10899.41M | 10899.41M | 10899.41M | 10899.41M | 11349.00M |
| Retained earnings | 21135.90M | 19187.67M | 15196.59M | 11494.17M | 8744.94M |
| Other liab | - | 631.68M | 574.41M | 473.08M | 440.22M |
| Good will | 234.90M | 149.98M | 149.98M | 188.96M | 140.47M |
| Other assets | 1008.15M | 1342.49M | 1859.71M | 536.74M | 0.00000M |
| Cash | 10298.01M | 9283.64M | 7259.46M | 4118.24M | 4327.02M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 8958.00M | 7226.04M | 6301.84M | 6236.77M | 7232.65M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -9715.46300M | -9189.59800M | -6942.74400M | -3930.70100M | -4327.01964M |
| Short term debt | 295.56M | 38.42M | 223.84M | 97.23M | 0.00000M |
| Short long term debt | 153.48M | 0.00000M | 99.00M | 23.00M | 70.45M |
| Short long term debt total | 582.54M | 94.04M | 316.71M | 187.53M | 0.00000M |
| Other stockholder equity | -1837.77500M | 15087.26M | 11432.88M | 7562.31M | -4638.88300M |
| Property plant equipment | - | 9563.92M | 8934.34M | 9282.38M | 6692.22M |
| Total current assets | 23957.16M | 20336.50M | 15921.37M | 13696.96M | 13776.13M |
| Long term investments | - | - | - | - | 0.00000M |
| Net tangible assets | 28090.33M | 25410.82M | 21687.71M | 17145.18M | 14111.54M |
| Short term investments | 3574.86M | 1443.41M | 1535.21M | 1838.69M | 2288.26M |
| Net receivables | 3937.97M | 6548.65M | 4744.78M | 4837.06M | 3887.34M |
| Long term debt | 28.95M | - | - | 0.00000M | 0.00000M |
| Inventory | 2554.86M | 2480.37M | 1861.07M | 2535.74M | 3039.28M |
| Accounts payable | 2010.07M | 1622.62M | 1241.57M | 1427.02M | 3267.34M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | - | - | - | - | 0.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 8868.33M | 4601.85M | 5666.60M | 4665.01M | 1244.02M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 17812.61M | 14405.07M | 14148.84M | 12621.36M | 9394.69M |
| Capital lease obligations | 400.11M | 94.04M | 217.71M | 164.53M | 0.00000M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -6795.98400M | 630.71M | -450.05600M | 261.06M | -1436.21600M |
| Change to liabilities | 487.07M | 232.57M | 629.28M | -572.97300M | 593.83M |
| Total cashflows from investing activities | -6795.98400M | -637.32600M | -2129.51300M | -2457.19300M | -3627.87100M |
| Net borrowings | -135.23900M | -222.16700M | 76.68M | -1634.30700M | 714.11M |
| Total cash from financing activities | -1904.07300M | -2196.60600M | -1470.97600M | -1545.53900M | -157.32196M |
| Change to operating activities | 920.34M | -59.87200M | 894.92M | -224.41100M | 770.40M |
| Net income | 7582.26M | 6847.10M | 6391.02M | 4626.16M | 3953.56M |
| Change in cash | -1058.85700M | 1800.25M | 3141.22M | -217.37700M | 1678.01M |
| Begin period cash flow | 9059.71M | 7259.46M | 4118.24M | 4335.61M | 4534.74M |
| End period cash flow | 8000.85M | 9059.71M | 7259.46M | 4118.24M | 1678.01M |
| Total cash from operating activities | 7627.06M | 4636.63M | 6739.61M | 3783.90M | 3953.56M |
| Issuance of capital stock | - | - | 0.00000M | 1223.50M | 0.00000M |
| Depreciation | 1047.94M | 865.47M | 808.81M | 691.60M | 607.41M |
| Other cashflows from investing activities | 308.74M | 269.00M | -10.01400M | -267.20200M | -190.05100M |
| Dividends paid | 2096.96M | 1690.76M | 1527.69M | 965.38M | 782.88M |
| Change to inventory | -42.75000M | -617.06700M | 601.44M | 509.31M | -614.03100M |
| Change to account receivables | -566.54800M | -943.55200M | -445.45200M | -196.74200M | -519.66200M |
| Sale purchase of stock | -14.21100M | -263.51200M | 0.00000M | -100.70600M | -86.81910M |
| Other cashflows from financing activities | 702.81M | -143.33100M | 56.72M | -1632.35900M | -2118.23705M |
| Change to netincome | -310.38500M | -446.11100M | -909.02900M | -136.99000M | -145.89600M |
| Capital expenditures | 2722.69M | 1758.45M | 1576.61M | 2122.67M | 2004.13M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | 798.12M | -1387.91800M | 1680.18M | -484.81100M | 179.37M |
| Stock based compensation | 160.73M | 17.73M | 9.13M | 6.72M | - |
| Other non cash items | -1961.98200M | -1705.75400M | -2149.52300M | -1055.76700M | -3953.56420M |
| Free cash flow | 4904.37M | 2878.18M | 5163.00M | 1661.23M | 1949.44M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CSPCY CSPC Pharmaceutical Group Limited |
- -% | 2.44 | 12.10 | 11.09 | 0.33 | 2.27 | 0.28 | 1.16 |
| LLY Eli Lilly and Company |
-0.61 0.08% | 795.67 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
0.58 0.40% | 145.85 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
1.61 0.90% | 180.00 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
0.08 0.08% | 99.45 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
No. 226 Huanghe Street, Shijiazhuang, China, 050035
| Name | Title | Year Born |
|---|---|---|
| Mr. Dongchen Cai | Exec. Chairman | 1954 |
| Mr. Cuilong Zhang | Vice-Chairman & CEO | 1969 |
| Mr. Chunlei Li | Exec. Director & Chief Scientist | 1976 |
| Mr. Kin Man Chak | Exec. Director | 1966 |
| Mr. Weidong Pan | Exec. Director | 1970 |
| Mr. Huaiyu Wang | Exec. Director | 1963 |
| Mr. Zhenguo Wang | Exec. Director | 1970 |
| Dr. Qingxi Wang | Exec. Director | 1966 |
| Dr. Hao Jiang | Exec. Director | 1983 |
| Mr. Jinxu Wang | Sr. VP | 1971 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...